Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia

被引:0
作者
L S Steelman
S L Abrams
J Whelan
F E Bertrand
D E Ludwig
J Bäsecke
M Libra
F Stivala
M Milella
A Tafuri
P Lunghi
A Bonati
A M Martelli
J A McCubrey
机构
[1] Brody School of Medicine,Department of Microbiology and Immunology
[2] East Carolina University,Division of Hematology and Oncology, Department of Medicine
[3] ImClone Systems,Department of Biomedical Sciences
[4] Georg-August University,Department of Cellular Biotechnology and Hematology
[5] University of Catania,Department of Clinical Sciences
[6] Regina Elena Cancer Center,Department of Human Anatomical Sciences
[7] University La Sapienza of Rome,undefined
[8] University of Parma,undefined
[9] Unit of Hematology and Bone-Marrow Transplantation,undefined
[10] University Hospital of Parma,undefined
[11] University of Bologna,undefined
[12] IGM-CNR,undefined
[13] c/o IOR,undefined
来源
Leukemia | 2008年 / 22卷
关键词
Raf; PI3K; Akt; signal transduction; inhibitors; chemotherapeutic drugs;
D O I
暂无
中图分类号
学科分类号
摘要
Mutations and chromosomal translocations occur in leukemic cells that result in elevated expression or constitutive activation of various growth factor receptors and downstream kinases. The Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways are often activated by mutations in upstream genes. The Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways are regulated by upstream Ras that is frequently mutated in human cancer. Recently, it has been observed that the FLT-3 and Jak kinases and the phosphatase and tensin homologue deleted on chromosome 10 (PTEN) phosphatase are also frequently mutated or their expression is altered in certain hematopoietic neoplasms. Many of the events elicited by the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways have direct effects on survival pathways. Aberrant regulation of the survival pathways can contribute to uncontrolled cell growth and lead to leukemia. In this review, we describe the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT signaling cascades and summarize recent data regarding the regulation and mutation status of these pathways and their involvement in leukemia.
引用
收藏
页码:686 / 707
页数:21
相关论文
共 50 条
  • [21] Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells
    John G Shelton
    Linda S Steelman
    John T Lee
    Steven L Knapp
    William L Blalock
    Phillip W Moye
    Richard A Franklin
    Steven C Pohnert
    Amer M Mirza
    Martin McMahon
    James A McCubrey
    [J]. Oncogene, 2003, 22 : 2478 - 2492
  • [22] Thymoquinone Inhibits JAK/STAT and PI3K/Akt/ mTOR Signaling Pathways in MV4-11 and K562 Myeloid Leukemia Cells
    Al-Rawashde, Futoon Abedrabbu
    Al-wajeeh, Abdullah Saleh
    Vishkaei, Mansoureh Nazari
    Saad, Hanan Kamel M.
    Johan, Muhammad Farid
    Taib, Wan Rohani Wan
    Ismail, Imilia
    Al-Jamal, Hamid Ali Nagi
    [J]. PHARMACEUTICALS, 2022, 15 (09)
  • [23] Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
    Butler, Dominika E.
    Marlein, Christopher
    Walker, Hannah F.
    Frame, Fiona M.
    Mann, Vincent M.
    Simms, Matthew S.
    Davies, Barry R.
    Collins, Anne T.
    Maitland, Norman J.
    [J]. ONCOTARGET, 2017, 8 (34) : 56698 - 56713
  • [24] A Novel Antithrombocytopenia Agent, Rhizoma cibotii, Promotes Megakaryopoiesis and Thrombopoiesis through the PI3K/AKT, MEK/ERK, and JAK2/STAT3 Signaling Pathways
    Chen, Wang
    Zhu, Linjie
    Wang, Long
    Zeng, Jing
    Wen, Min
    Xu, Xiyan
    Zou, LiLe
    Huang, Feihong
    Huang, Qianqian
    Qin, Dalian
    Mei, Qibing
    Yang, Jing
    Wang, Qiaozhi
    Wu, Jianming
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [25] Tanshinone IIA can inhibit MiaPaCa-2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways
    Su, Chin-Cheng
    [J]. ONCOLOGY REPORTS, 2018, 40 (05) : 3102 - 3111
  • [26] Recent Developments in Targeted Therapies of the RAF-MEK and PI3K-AKT Pathways in Cancer Treatment
    Cremers, Lobke G. M.
    Boonstra, Johannes
    [J]. CURRENT CANCER THERAPY REVIEWS, 2012, 8 (03) : 205 - 217
  • [27] Targeting PI3K/AKT/mTOR network for treatment of leukemia
    Bertacchini, Jessika
    Heidari, Nazanin
    Mediani, Laura
    Capitani, Silvano
    Shahjahani, Mohammad
    Ahmadzadeh, Ahmad
    Saki, Najmaldin
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2015, 72 (12) : 2337 - 2347
  • [28] Targeting PI3K/AKT/mTOR network for treatment of leukemia
    Jessika Bertacchini
    Nazanin Heidari
    Laura Mediani
    Silvano Capitani
    Mohammad Shahjahani
    Ahmad Ahmadzadeh
    Najmaldin Saki
    [J]. Cellular and Molecular Life Sciences, 2015, 72 : 2337 - 2347
  • [29] IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways
    Bibollet-Bahena, Olivia
    Almazan, Guillermina
    [J]. JOURNAL OF NEUROCHEMISTRY, 2009, 109 (05) : 1440 - 1451
  • [30] Benzimidazoisoquinoline derivatives inhibit glioblastoma cell proliferation through down-regulating Raf/MEK/ERK and PI3K/AKT pathways
    Zhang, Ya-Jun
    Xu, Zhi-Gang
    Li, Shi-Qiang
    He, Liu-Jun
    Tang, Yan
    Chen, Zhong-Zhu
    Yang, Dong-Lin
    [J]. CANCER CELL INTERNATIONAL, 2018, 18